Literature DB >> 24628236

Current view on the mechanism of action of perifosine in cancer.

Joachim Fensterle, Babette Aicher, Irene Seipelt, Michael Teifel, Juergen Engel1.   

Abstract

Perifosine treatment exhibits a complex molecular response including the inhibition of Akt or the induction of apoptosis via clustering of death receptors in lipid rafts. However, the molecular response can vary between different tumor entities and the contribution of each target pathway to the activity of Perifosine might be distinct depending on the tumor entity or the agent combined with Perifosine. In this review we discuss the current view on the mechanism of action of perifosine in cancer and the contribution of the molecular targets of Perifosine to its activity.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24628236     DOI： 10.2174/1871520614666140309225912

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN： 1871-5206            Impact factor:   2.505


  17 in total

1.  Chlorogenic acid inhibits hypoxia-induced angiogenesis via down-regulation of the HIF-1α/AKT pathway.

Authors:  Jin Ju Park; Su Jung Hwang; Ji-Hyeon Park; Hyo-Jong Lee
Journal:  Cell Oncol (Dordr)       Date:  2015-01-06       Impact factor: 6.730

2.  Perifosine Mechanisms of Action in Leishmania Species.

Authors:  Atteneri López-Arencibia; Carmen Martín-Navarro; Ines Sifaoui; María Reyes-Batlle; Carolina Wagner; Jacob Lorenzo-Morales; Sutherland K Maciver; José E Piñero
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

3.  Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo.

Authors:  Jianli Zhang; Yue Hong; Jie Shen
Journal:  Tumour Biol       Date:  2015-02-20

4.  Caenorhabditis elegans as a platform to study the mechanism of action of synthetic antitumor lipids.

Authors:  Adolfo Sánchez-Blanco; Alberto G Rodríguez-Matellán; Mariana Reis-Sobreiro; Beatriz Sáenz-Narciso; Juan Cabello; William A Mohler; Faustino Mollinedo
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

5.  Preclinical evaluation of perifosine as a potential promising anti-rhabdomyosarcoma agent.

Authors:  Jie Shen; Yue Hong; Qiong Zhao; Jian-Li Zhang
Journal:  Tumour Biol       Date:  2015-08-13

6.  Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines.

Authors:  Stefan Hausmann; Evelyn Brandt; Carolin Köchel; Hermann Einsele; Ralf C Bargou; Ruth Seggewiss-Bernhardt; Thorsten Stühmer
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

7.  Endoplasmic reticulum targeting in Ewing's sarcoma by the alkylphospholipid analog edelfosine.

Authors:  Ximena Bonilla; El-Habib Dakir; Faustino Mollinedo; Consuelo Gajate
Journal:  Oncotarget       Date:  2015-06-10

8.  Targeting the raft-associated Akt signaling in hepatocellular carcinoma.

Authors:  Yuan Liu; Ji-Yun Lv; Jian-Fei Shi; Mei Yang; Shu-Hong Liu; Zhi-Wei Li; Hong-Bo Wang; Shao-Geng Zhang; Zhen-Wen Liu; Jin-Biao Ding; Dong-Ping Xu; Jing-Min Zhao
Journal:  Biomed Res Int       Date:  2014-08-27       Impact factor: 3.411

Review 9.  Posttranslational regulation of Akt in human cancer.

Authors:  Chia-Hsin Chan; Ukhyun Jo; Abraham Kohrman; Abdol Hossein Rezaeian; Ping-Chieh Chou; Christopher Logothetis; Hui-Kuan Lin
Journal:  Cell Biosci       Date:  2014-10-01       Impact factor: 7.133

10.  Down-Regulation of AKT Signalling by Ursolic Acid Induces Intrinsic Apoptosis and Sensitization to Doxorubicin in Soft Tissue Sarcoma.

Authors:  Victor Hugo Villar; Oliver Vögler; Francisca Barceló; Javier Martín-Broto; Jordi Martínez-Serra; Valentina Ruiz-Gutiérrez; Regina Alemany
Journal:  PLoS One       Date:  2016-05-24       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.